A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
Status:
Recruiting
Trial end date:
2024-06-04
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and
pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune
disease(s).